The Prostate · 2026
A Gene Expression Tumor Signature Optimizing Partial Area-Under-the-Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gerke Travis A, Tyekucheva Svitlana, Stopsack Konrad H, Sweeney Christopher J, Lis Rosina T, Westling Elizabeth N, Loda Massimo, Stampfer Meir J, Penney Kathryn L, Parmigiani Giovanni, Mucci Lorelei A
Аннотация
PURPOSE: A key clinical challenge in prostate cancer is the identification and validation of biomarkers with high specificity for indolent long-term outcomes. We applied a novel statistical method to identify tumor transcriptomic biomarkers that optimally predicted patients with low metastatic potential.
METHODS: Using tumor whole-transcriptome data from the Health Professionals Follow-up Study (HPFS, discovery set) and Physicians' Health Study (PHS, validation set), we compared patients who died of prostate cancer or developed metastases ("lethal," n = 113) and patients with > 8 years of metastasis-free survival ("indolent," n = 291). Whole transcriptome tumor gene expression data were generated using an Affymetrix array. We applied a novel method for optimizing a partial area under the curve (pAUC) that up-weighted indolent cases with a predefined 80%-100% specificity. This method leverages weighted logistic lasso regression, with weights chosen via cross-validation to reduce overfitting.
RESULTS: Median age at cancer diagnosis was 66 years; median follow-up for outcomes was 14 years. We identified a 40-gene transcriptome signature of indolent prostate cancer, which, compared to Gleason grade groups, improved the pAUC over the predefined 80%-100% specificity range by 1.72-fold (p < 0.001) and improved overall AUC from 0.85 to 0.93 (p < 0.001). The signature improved positive predictive value for indolent tumors > 2-fold with minimal decrease in negative predictive value. Importantly, the 40-gene signature showed high discrimination among intermediate Gleason 7 tumors (Grade groups 2 and 3, AUC 0.88, 95% CI: 0.79-0.95).
CONCLUSION: Incorporating pAUC into prognostic signature development improved identification of prostate tumors with low risk of metastatic potential. Its clinical application may help reduce overtreatment and overdiagnosis of indolent prostate cancers, and the pAUC may be relevant beyond prostate cancer.
METHODS: Using tumor whole-transcriptome data from the Health Professionals Follow-up Study (HPFS, discovery set) and Physicians' Health Study (PHS, validation set), we compared patients who died of prostate cancer or developed metastases ("lethal," n = 113) and patients with > 8 years of metastasis-free survival ("indolent," n = 291). Whole transcriptome tumor gene expression data were generated using an Affymetrix array. We applied a novel method for optimizing a partial area under the curve (pAUC) that up-weighted indolent cases with a predefined 80%-100% specificity. This method leverages weighted logistic lasso regression, with weights chosen via cross-validation to reduce overfitting.
RESULTS: Median age at cancer diagnosis was 66 years; median follow-up for outcomes was 14 years. We identified a 40-gene transcriptome signature of indolent prostate cancer, which, compared to Gleason grade groups, improved the pAUC over the predefined 80%-100% specificity range by 1.72-fold (p < 0.001) and improved overall AUC from 0.85 to 0.93 (p < 0.001). The signature improved positive predictive value for indolent tumors > 2-fold with minimal decrease in negative predictive value. Importantly, the 40-gene signature showed high discrimination among intermediate Gleason 7 tumors (Grade groups 2 and 3, AUC 0.88, 95% CI: 0.79-0.95).
CONCLUSION: Incorporating pAUC into prognostic signature development improved identification of prostate tumors with low risk of metastatic potential. Its clinical application may help reduce overtreatment and overdiagnosis of indolent prostate cancers, and the pAUC may be relevant beyond prostate cancer.